Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility

- Removal of Minimum Liquidity Covenant of US$30 Million if F8 Formulation of Tesamorelin is Not Approved by the FDA by March 31, 2024- Minimum Li...

Related Keywords

Montreal ,Quebec ,Canada ,United States ,Toronto ,Ontario ,Philippe Dubuc ,Julie Schneiderman ,Toronto Stock Exchange ,Company Auditors ,Communications Corporate Affairs ,Drug Administration ,Theratechnologies Inc ,Minimum Liquidity Covenant ,Not Approved ,Liquidity Covenant ,Decrease Over Time ,Targeted Adjusted ,Going Concern Note ,Annual Report ,Marathon Asset Management ,Loan Facility ,United States Food ,Forward Looking Statements ,Looking Statements ,Annual Information Form ,Vice President ,Chief Financial Officer ,